Tuesday, January 19, 2021
Home Latest News Cell2in completes technology development for target disease cell therapy!... Preparing for...

[19th MIK 2020 SEASON OFF ONLINE] Cell2in completes technology development for target disease cell therapy!… Preparing for MFDS approval

Cell2in is participating in the 19th MIK 2020 SEASON OFF ONLINE ZOOM event on Dec. 8, 4:00 pm as a part of KHIDI project.

Cell2in was founded in 2016 as a spin-off company from SNU College of Medicine. By independently developing FreSHtracer, a base technology that can measure the cell quality of high-quality cell therapy products, it has secured an innovative source technology that can check the quality of cell therapy products such as stem cells. By applying this to the industry, it is discovering high-quality cell therapy products, customized cell culture media, animal stem cell therapy products, cell-derived exosomes, cell quality control system equipment, and new anti-aging substances.

Particularly, by intensively developing cell therapy products for autoimmune and inflammatory adverse reaction diseases based on cell quality control technology, it is developing cell therapy production technology with high quality and consistent therapeutic effect. △ Status of patents owned: 7 registered (5 in Korea, 2 in the US), 18 applied (9 in Korea, 5 in the US, 3 in Europe, 3 in China, 3 in Japan, 1 in Canada, 1 in Australia, and 1 in India)

The company staff said, “The stem cell therapy product being developed by our company is a new paradigm that introduces cell quality control into the manufacturing process, and the problems of the existing cell therapy products which are the lack of consistency of cell quality in batches the lack of trust on the treatment effect of cell therapy products and maintaining high quality have been solved.”

He then said, “We would like to contribute to the improvement of cell therapy products in the future by proving the effectiveness using our independently developed cell quality evaluation platform technology to prove efficacy, and applying for registration to the US FDA for use by R&D institutions as guidelines for measuring cell quality. We have completed the technology development for cell therapy products for target diseases and we are preparing to get MFDS approval.”

The 19th MIK 2020 SEASON OFF ONLINE is hosted by AVING NEWS, the media partner of more than 100 trade shows including MWC and IFA that has established a global news network with major media companies in 54 countries. This time, seven media, Vietnamplus from Vietnam, Myfatpocket from Singapore, Geekazine from the US, SINA from China, LeCafeduGeek from France, IT DONGA from Korea, SVPRESSA.RU from Russia, and STARTUPWORLD.TECH from France will be participating to publicize the participants to the world.

In this event, 24 companies will participate with support from Korea Health Industry Development Institute (KHIDI), Gwangju Information & Culture Industry Promotion Agency (GITCT), Daejeon Information & Culture Industry Promotion Agency (DICIA), Seoul Startup Hub Seongsu, and Twosun Campus. △IBS Tech △Awesomepia △BA Energy △CiSTEM △Biotruss △Wellmarker Bio △CM Lab △Cell2in △SKIMS-Bio △Caredoc △Libest △THE.WAVE.TALK △Dotrade △Linkoptics △Geniesoft △Ghostpass △SafeTech Research △Myung Kwang Chemical △Multics △Batoners △THES △J2 △Myungsung Corporation △Baice

→ Go to 19th MIK 2020 SEASON OFF ONLINE news page

- Advertisment -

Most Popular

Recent Comments